Atomo NewsGet the app

Get the latest Science News and Discoveries

Aumolertinib plus chemotherapy improves progression-free survival in NSCLC with EGFR and concomitant tumor suppressor genes: ACROSS 2 phase III study - EurekAlert!


Comprehensive up-to-date news coverage, aggregated from sources all over the world by Google News.

None

Get the Android app

Or read this on Eureka Alert

Read more on:

Photo of Chemotherapy

Chemotherapy

Photo of aumolertinib

aumolertinib

Photo of Progression

Progression

Related news:

News photo

Ivonescimab plus chemotherapy improves progression-free survival in patients with EGFR+ NSCLC following 3rd-generation EGFR-TKI therapy - EurekAlert!

News photo

Crizotinib fails to improve disease-free survival in resected early-stage ALK+ NSCLC - EurekAlert!

News photo

Zidesamtinib shows durable responses in ROS1 TKI pre-treated NSCLC, including patients with CNS disease and ROS1 G2032R mutations - EurekAlert!

« Ivonescimab plus chemotherapy improves progression-free survival in patients with EGFR+ NSCLC following 3rd-generation EGFR-TKI therapy - EurekAlert!
FLAURA2 trial shows osimertinib plus chemotherapy improves overall survival in eGFR-mutated advanced NSCLC - EurekAlert! »